CVC, GBL Secure 91.9% of Recordati

The consortium's stake surpasses the 90% threshold needed to delist the Italian pharmaceutical group.

Updated on Nov. 9, 2026 in Healthcare

Isometric editorial illustration of two rows of plain amber glass vials of differing heights on a cream surface, a taller majority group outlined against a shorter group.
CVC and GBL secured 91.9% of Recordati on Monday after their €53-per-share takeover offer closed, clearing the 90% threshold needed to delist the Italian drugmaker. AI Illustration. Upload story photo >

CVC and GBL secured more than 90% of Recordati at the close of their takeover offer on Monday, lifting their holding to 91.9%. The consortium offered €53 per share for the Italian pharmaceutical group, which is valued at €11 billion ($12.32 billion).

Why it matters

Passing the 90% mark allows the consortium to move toward delisting Recordati from the stock market. The result gives the buyers near-complete control of a major European drugmaker.

The consortium's 91.9% stake, calculated by Reuters from Borsa Italiana data, sits 1.9 percentage points above the 90% delisting threshold. The figure excludes any shares CVC or GBL acquired on the market on Monday, so the final holding may differ.

The players

CVC Capital Partners

CVC Capital Partners is a global private equity firm that co-led the takeover bid for Recordati alongside GBL.

GBL

GBL, formerly Groupe Bruxelles Lambert, is a Belgian investment holding company that co-led the takeover bid for Recordati with CVC.

Recordati

Recordati is an Italian pharmaceutical group, listed on the Borsa Italiana, that is the target of the takeover bid.

The details

CVC and GBL, acting together, offered €53 per share in the takeover bid for Recordati. Additional shares tendered on Monday pushed the holding above the 90% level before the offer closed at 1630 GMT.

Timeline

  1. Monday, November 9, 2026: Takeover offer closed at 1630 GMT and the consortium passed the 90% threshold.

Market Landscape

The bid reflects a wider pattern of private equity groups taking listed European drugmakers private, removing them from public markets. Such deals consolidate control of pharmaceutical assets among a small number of large investors.

Once Recordati is delisted, its shares will no longer trade on public markets, changing how ordinary investors can hold the company. Patients and healthcare providers are unlikely to see immediate changes from the ownership shift alone.

The takeaway

Large investors are increasingly acquiring listed drugmakers and taking them private. Readers who hold shares in European pharmaceutical firms should watch for delisting notices following a takeover.

Further reading

Explore more reporting in the Healthcare section for context on drug industry deals.